MAP2K7 and non-small cell lung carcinoma: They found that NSCLC cell lines carrying the KRASG12D mutation have activated phosphatidylinositol 3-kinase (PI3K) and mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) signaling pathways.